ReviewCurrent pain and headache reports2025
Cooled Radiofrequency Ablation of the Lateral Femoral Cutaneous Nerve for Chronic Refractory Meralgia Paresthetica.
Review in Current pain and headache reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChronic pain affects over 51 million people and is associated with a poor quality of life. Meralgia Paresthetica is a chronic pain condition resulting from injury to the lateral femoral cutaneous nerve. Radiofrequency ablation (RFA) is a minimally invasive treatment option that has demonstrated efficacy for several nerve targets. However, limited research has focused on RFA targeting the lateral femoral cutaneous nerve. This is the first study to date to investigate the outcomes of cooled RFA for the treating of refractory Meralgia Paresthetica. RECENT
findingsData were retrospectively collected from the electronic medical records of patients treated with cooled lateral femoral cutaneous nerve RFA for Meralgia Paresthetica between 2014 and 2025. Eleven cases involving seven patients were included in this study. VAS scores decreased from 5.91 ± 1.22 at baseline to 3.05 ± 2.64 at follow-up (p < 0.001). Patients in nine of the eleven cases reported improvement in pain, with an average reduction of 64.8%. Duration of pain relief after cooled RFA was 6.92 ± 3.23 months for six cases with this data available. Cooled lateral femoral cutaneous nerve RFA is effective for many patients with Meralgia Paresthetica and may be offered for refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.